Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Nightingale Health 2025–2026 Results Webcast

By Inderes9/16/2026, 11:00 AM
Nightingale Health

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Teemu Suna
00:00 - 42:40

Good afternoon and welcome to the Nightingale Health Financial Year 2025–2026 webcast. My name is Teemu Suna. I am the CEO and founder of Nightingale Health. I am currently also the CFO of the company. Today our agenda is that I will first talk about Nightingale Health. Then we will go through the business targets of the past fiscal year. Then we look into the business targets of the current fiscal year. Then we will have a business update. I will go through the different business areas. Then we will have the financial review. Then we look at the AGM and financial calendar. Then we have some significant events after the end of the period. And then in the end we have Q&A, and you can post your questions. We will go through them in the Q&A at the end. So let's start. So, Nightingale Health, we are a global health technology company. We have been building the company for more than ten years. We have a global footprint. We run our own laboratories in the US, UK, Finland, Japan, and Singapore. We work in B2B and B2G markets. And the main focus is preventive healthcare. So what is Nightingale all about? We have created a preventive healthcare platform, which enables various AI-powered applications. The problem with basically all healthcare applications today is that there is no globally standardized, clinical-grade way to measure health trajectories and intervention impact. So we actually take actions in healthcare, but we do not know what the impact of those actions is. We operate many times blindly. This is particularly true when it comes to lifestyle interventions. The solution is that we take a single blood sample. We run one test and we detect the risk of developing diseases in the future. So we detect if a healthy individual is at risk of developing many cardiometabolic diseases, such as type 2 diabetes, cardiovascular disease, and kidney disease. Fatty liver disease. This platform has been built, as I said, over the past ten years. It has very strong validation. We have run more than 3 million samples. There are more than 1,000 peer-reviewed publications of the technology, and the footprint is global, and the technology is already in national use in Finland. The opportunity here is significant. We enable the standardized global measurement layer to power all the healthcare applications, particularly when they are AI-native. And this preventive healthcare problem is applicable across all fields of healthcare, including payers, providers, and population-scale programs. So the solution, in a more detailed way, is that we take a single blood sample. This is a standard blood sample. It is venous or it can be a fingerprick. We have our own proprietary device. This is how we collect the sample. Then we take that sample. We run our own biotechnology platform based on NMR metabolomics. In that test, we detect very broad biological information from the blood. And because we can detect very broad biological information, more than 40 clinical biomarkers, we have developed validated risk models that go beyond the biomarkers. So we detect the risks of developing diseases such as heart attack, stroke, type 2 diabetes, chronic kidney disease, and liver disease in one go. So we are not a traditional diagnostics company focused on single biomarkers. We quantify disease risk. And this is important, because if you really think about it. Nobody is truly interested. What is your LDL cholesterol? As a matter of fact, 70% of people who have a heart attack have normal LDL. So if nobody is interested in the biomarkers, or if the biomarkers really don't tell the story. So then the whole industry is working around the biomarkers. So we have created something better. This goes beyond the biomarkers. This quantifies the risk. So instead of knowing what your LDL level is, you should know what your risk of developing a heart attack is. And then when you take actions, such as lifestyle changes or medication, it can be anything like exercise, sleep, or diet. Then we measure you again and we can quantify if your actual risk is going down. And this is important because why would you measure your blood if you cannot measure if your risk of developing the actual disease is going down. So that's why we are not a traditional diagnostic company. We actually quantify the disease risk. And this is what other diagnostic companies cannot. They cannot do that. Why risk detection is very important now. First of all, the chronic disease burden of the diseases that I mentioned. It is all around. It is all around the world. This is if you take all of the healthcare costs; depending on how you calculate this, someone may say this is like 60% of all the costs. You can also argue that it is closer to 90% of all costs, which are related to chronic diseases. And the reason is that chronic diseases by nature are long-standing diseases that need attention all the time. So this creates a huge cost pressure. It is accelerating around the world. Then the second point: prevention is going mainstream in population-scale programs. So it is not that the market is not there; the market is there and it is expanding rapidly. When we started this company, I remember almost 15 years ago when I was talking about preventive healthcare, it was something that was mostly limited to keynote speeches where people would talk about it, but nobody was taking any action. Today, the situation is very different. So we have a lot of preventive healthcare programs ongoing around the world. They are in the early days, but it is very clear that this will be the new standard of primary care. Number three, AI is driving the transformation in healthcare everywhere. When we talk about AI, we often refer to data centers and algorithms. If you look now, what is the most advanced conversation around AI? It is all around data because data is the fuel for the AI. If you don't have good data, you cannot generate biological data of people. You have to measure it, and you have to get the data. And then on the other hand, when AI applications get the data, if you think about the big health platforms, if they have high-quality, objective, standardized molecular data. It will transform what these applications can do. And this is what Nightingale Health will enable. And we have a very unique platform to enable it. Building this kind of company is a long journey, a very long journey. The reason for this is that you have various very complicated elements. So we started by creating the biotechnology and building a biotechnology platform. The amount of scientific work, engineering work, and particularly the validation work and regulatory work is immense. And you have to build all of that first before you can do any applications. In our case, it had two different parts. The first part was to validate the platform and to detect the biomarkers. And then the second part was to validate the risk models. The risk models we have today feature a level of validation that is unmatched in the market worldwide. So we are a global leader in this. But it has taken a decade to build it up. Then building even that is not enough because then you have to build the capability to deliver the product. So you have to build the laboratory network because we are not using the standard laboratories, as the equipment and technologies they are using are not sufficient for what we want to do. They are not suitable for what the market actually needs to happen. They are built for single biomarker detection. The market. The future of healthcare in primary care is holistic health profiling. So we could not go to the existing labs and say that we were going to do this with these technologies. And this is very heavily validated by many scientific publications where we have been compared against standard clinical chemistry measurements. And the results are very clear that our risk detection performance goes beyond the standard routine protocols in biomarker detection. So how does this journey, if you put it in a timeline, how does this journey look like, so we started from Finland. We built it. Built our laboratory in our headquarters. Starting in 2015. First you. You. You do the pilots without the local lab. Then you build the local lab. Then you get the regulatory approvals. Then you win the local pilots. Then you try to win the local reference deals, and then you try to get the volumes up. Then after Finland, we started to build Japan, then Singapore, UK, US. And now you can see that the timeline accelerates heavily. So Finland was 2015 and now in two years Singapore, UK, US. And this is because the expansion model and the way we have standardized the lab rollout. We have it completed. So when we expand to more countries, we can basically take this technology anywhere in the world. And now after these five locations, which we needed to invest heavily upfront ourselves. Now when going to new regions, we do it with a very commercial model. The business model, as I mentioned, is that we work with B2B customers. They embed Nightingale Health's data in their preventive health applications. We have basically, you can think of this as a tiered structure. So depending on the volume, because this is heavily a volume business. So the more volume you have, the better you can manage the process, perform it in a more affordable manner, and achieve lower unit prices. This technology is not built for the longevity field, where the richest 1% in the world can use this technology and feel good about it. This is built to build a healthier world. It means that we need to integrate into the healthcare systems. But I think more importantly, we need to deliver health information that is built for humans. And this is what we do. So as I mentioned earlier, instead of telling you what your LDL is? What is your ApoB or ApoA1? What is your biomarker profile? Yes, we also provide that information. But if you think about the population, and if you really think about healthcare globally, the real problems and challenges that we need to solve are not related to a distinct group of people who are very familiar with all the biomarkers and metabolic pathways, etc. That is not the point. The point is to deliver information that anyone can use to live a healthier life. And that is what we do. That's the focus. That is why we also aim for high-volume applications. We aim to push the price down, not up. It is a hard thing to do. It is actually a much harder thing to do than going into these high-end luxury markets. But that is why we started the company and that is what we are going to do. And when we get it done. There is also an immense global business opportunity that we aim to capture. To that end, the market is there. It is huge. I think the main point in this slide is that if we look at the global wellness economy, I said that this is what we built. We built this for the people. We are not going directly to consumers to sell our services to people. But the world is full of these major scale health platforms that will significantly benefit from Nightingale's data when they integrate it into their applications. This is how we can reach the global wellness economy and how the global wellness economy is $6.3 trillion. But that is a reflection of the market that we want to be. And that is the future of healthcare. Primary healthcare will not happen as a part of the healthcare system that we have currently. It is not hospitals. That is the sick care system. The healthcare system is where you meet the people. And to connect with people, you need to show them data that they can understand, that they can use, and that they can use to improve their health. Nightingale is the ability to detect the risks and follow the change of the risk. When people take actions, change their lifestyle, etc. So building the globally standardized clinical-grade measurement layer is the key that powers the whole world of preventive healthcare as well as the global wellness economy. And this is the opportunity also with Nightingale, specifically the capability of detecting chronic disease risks. This is where we are a world-leading company. So why Nightingale and what makes us unique. Validation is second to none. We are global. This is an asset that is not regional. If you think about the current diagnostics industry, you can take the biggest player in the United States. You take Quest Diagnostics and LabCorp of America. They are not global. You take the biggest player in Europe. You look at Synlab. They are not global. So. But we are. And we are independent. We are not dependent on any of the existing laboratory networks. We have built our own. This is only available from Nightingale Health. What we do in terms of risk detection and, importantly, clinically validated risk detection. It is only available from Nightingale Health. Any engineer can build this kind of a model. You just take some biomarkers and you take some data and then you build some kind of a risk model and you say, oh, here is my risk model, but it is not a validated model. It is a completely different thing. And when you start building global health applications, it is better for all of us if the technologies that the health platforms use are validated with the highest possible standard. And this is what we have; the data that this is based on, we are running on top of the world's largest NMR metabolomics database. The company has transparent operations as we are a public company. We have excellent scalability and excellent efficiency. In a global comparison, how efficiently we operate in terms of the use of funds, for example, is exceptional. And this technology is already adopted by nationwide healthcare here in Finland. So that is it. So I think it's a very important moment in our journey as a company, because what we have been building for a long time now. We very strongly feel that the market is also showing very clear indications that this prevention, holistic health profiling, the ability to detect outcome risks, objective measurements, repeatability, global footprint, and remote sampling are vital. If you take this and you take any of the big health platforms in the world, these are the things that are on top of their priority lists. And these are also things that are immensely difficult to build, taking a decade, yet we have achieved it. I am not aware that there is anyone else who is even close to what we have built. I would call that a moat, which is very, very important. Now, in this situation, the market is taking steps towards prevention and holistic health profiling. All right. Let's go to the business targets of the past fiscal year. Our target was to increase revenue by at least 50%. We landed only a 17% increase. We did not achieve the target. This is of course disappointing. We had the pipeline, we had the deals. We had everything set up in a way that we would reach the target. Unfortunately, there was about €2 million in revenue that got postponed in a single large project, and this was due to third parties. So we could not do anything about the situation. Now this €2 million moved to the current fiscal year. But of course, it was disappointing that we did not achieve the target. Now, when we look at the current fiscal year. So last year, the aim was to increase the revenues by 50%. Now it is approximately double. So approximately 100%. So we aim to achieve revenues of at least €10 million. We have only this single target. The reason for this is that now the most important thing is to increase the adoption of the technology, and revenue is a very efficient way to measure it. And we have full focus in building up the revenue streams across all of our businesses, in our research business, and in our healthcare business, all across the board. The mid-term and long-term business targets are unchanged. We strongly believe that these are still very relevant. And as I said, the problem we are solving here is a global problem. And this is the level we want to achieve with this technology. Then we have next the business update by geographical areas. In summary, we have been very focused on our commercial activities. I mean, the point here is that now it's time to increase the adoption. So it is time to win deals. And it's only to win deals. That is what matters now. We have a very strong focus towards that. We have made many changes in the company to enable more time and energy for commercial activities. So, in the last fiscal year, we have already made progress. We managed to increase the value of the sales pipeline. We signed new significant agreements. And we have had a lot of pilot projects launched. So the work we are doing is, I think we have done many important and right actions. If I look at the volume of commercial activities, it has increased significantly. We will continue increasing that. But it's also important to remember that in this business, the sales cycles are long. And even when you win new contracts, they typically ramp up step by step. It is not as if someone adopts the technology in large-scale use overnight. We also have those kinds of deals. But it is important to realize that the market dynamics are pretty slow in this industry. We go through country by country, and in Finland, I think we have a very strong market position here. We are in nationwide use. We have run more than 250,000 samples for people here in Finland already, which, given the population of 5 million, is pretty significant. We are also expanding into public healthcare use here in Finland. I think that's also very important because this is, as I mentioned earlier, a technology that is built to be part of the health system. It is a technology that enables a new kind of health system. And I'm thrilled to see that in Finland, the government also has a very progressive mindset to start building prevention. I said earlier that the current healthcare system will not build prevention. I still think this is true in the big picture. But then we have countries and we have programs that actually aim to transform the healthcare system in the right direction of prevention. And of course, it is very good to see this happening. In the UK, we have done a lot of market exploration work in the clinical side. We are very strong in the UK in the research business side of things, but now we have also put a lot of effort into the clinical side, with market exploration ongoing and the first pilot project launched; I expect to see more results from the UK already in the current half-year. In EMEA, we saw a lot of commercial activities over the past fiscal year, and we opened discussions in more than 20 countries. We started with market exploration style activities. We started from a market exploration style of activities. Aiming to close as many pilot programs as we can. Our pipeline for the pilots is very strong. We have announced some of the pilots already. And there is more to come. And next with these pilots, there is a lot of conversation to go into production stage negotiations. So the market is building well in EMEA. As I said, it takes time. It is important to note that last fiscal year was the first one that we had a strong commercial effort starting to build this up. So it takes some time. But when looking at the pipeline and the funnel, it looks very good and it grows all the time. The most important thing we did in Singapore was that we introduced a new version of the product based on customer feedback. Now there are customers who have been using the product and the feedback is very good. We are very happy about it. The volumes are initially modest, but we expect the volumes also to increase steadily. It is also the health screening market that we work in in Singapore. It is not the same around the year. So there are certain time periods in a year when there is more demand. We will now see how the demand develops when we move into the high season of health screenings in Singapore. In Japan, we have also done a lot of work with the customer feedback that we have got from the recurring customers. There are improvements that belong to the business model and the report over the coming months. Initial conversations have already taken place with the customers and the feedback about the improvements is very good. Having a good product-market fit is essential. That is why we are taking these actions to help to build the business up. But the first commercial results of the new products in Singapore and in Japan are expected also in the current fiscal year. In the United States, I think a very important step was that we. And the pipeline for the pilots is very strong. We have announced some of the pilots already. And there is more to come. And next with these pilots, there are a lot of conversations to go into production stage negotiations. So the market is building well in EMEA. As I said, it takes time. It is important to note that last fiscal year was the first one where we had a strong commercial effort starting to build this up. So it takes some time. But when looking at the pipeline and the funnel, it looks very good and it grows all the time. In Singapore, perhaps the most important thing we did was to introduce a new version of the product based on customer feedback. Now there are customers who have been using the product and the feedback is very good. So we are very happy about it. The volumes are initially modest, but we expect the volumes also to increase steadily. It is also the health screening market that we work in in Singapore. It is not the same throughout the year. So there are certain time periods in a year when there is more demand. And we will now see how the demand develops when we move into the high season of the. Of the health screenings in. In Singapore. In Japan, we have also done a lot of work with the customer feedback that we have received from the recurring customers. There are improvements belonging to the business model and the report. Over the coming months. Initial conversations have already taken place with the customers and the feedback about the improvements is very good. Having a good product-market fit is essential. And that is why we are taking these actions to help build the business up. But the first commercial results of the new products in Singapore and in Japan are expected also in the current fiscal year. In the United States. I believe a very important step was that we achieved that. We managed to receive the permit from the state of New York, and we have a clear roadmap to enter the US healthcare. Healthcare market. Now, because of this, we also hired a chief commercial officer located in the US. And we have several new sales activities initiated. There are a lot of pilot negotiations ongoing that would utilize the New York lab. The medical research market is still our biggest business area. We took strong actions to increase sales activities in this business area. We introduced the multi-omics offering. We announced a strategic partnership with Alamar Bioscience, so there are a lot of very strong commercial actions that we have taken. The pipeline has increased substantially. I am expecting to see more wins in this segment in the future. In the past fiscal year, we closed a couple of important projects. All right. That was the business update. I would summarize it in a way that one of the key strengths of Nightingale is that we are, as I said in the beginning. I will say it again. I will reiterate it. We are a global company, and the global company structure, even though it is very challenging to build, is now firmly in place. We have now built it. We have it going. The benefit of that structure is that we can execute in parallel in several markets. We can execute in parallel in several markets. We can learn from different markets at the same time. We can get those learnings to build a better product, and then we can deploy the products in these markets. Then if there are some disruptions, as we have seen, there may be disruptions around the world, and politics may change there. Various things may happen. But because we are operating globally, we are also in a position to continue growing the business, even if a country faces some challenges. And that is something that we are going to continue building as a global company, building it in parallel. And with that, we can also ensure that the business growth will take place. Then let's have a look at the financial review for the past fiscal year. We had the best half-year ever during the last half of the past fiscal year. The second half revenue increased by 30% compared to the second half of the previous fiscal year. And the revenue for the full year was 5.5 million. The largest part of our revenue still came from the research business. This is something that, when I look at the forward-looking pipeline, the balance is shifting step by step. So the healthcare part is taking a bigger and bigger part of the revenues. It just takes some time to build it up. I am very excited to see the research revenues growing because these two businesses that we have are not completely isolated. They are not. So when we win in research, it helps us to win in healthcare. When we win in healthcare, it helps us to win in research. It is the same technology. These are interlinked. It is the same company. These are interlinked. One of the unique abilities we have, which we have demonstrated, is the ability to translate scientific findings into clinical products. You can conduct a review and see how successful companies are in this; in general, it's very difficult. And we have. We have done it in a very difficult market. When we look at the primary care market. Now, when there are more scientific findings, we can translate these findings to clinical products very rapidly. And I think this is important to remember when evaluating the business between research and healthcare. They are both very important. Here are the financials. So the revenue growth was 17% compared to the last fiscal year. The change in liquid funds was more or less the same as in the previous year. So we can run the company without increasing the cost burden, which is important also when we are looking to increase the revenues. We have strong confidence that we can actually hold this. This cash position. And with the revenue increase, we are even starting to improve it. I think this is because we have the structures in place. Many times if you look at the numbers in technology growth companies, when the revenue starts going up, the amount of money going out increases. In our case, we expect this number to decrease, which tells a lot about the business structure that we have in place and the ability to grow. We are still in a solid financial position. We have a debt-free balance sheet. When looking at the business transformation that we are building, I am not worried about the financial position. I strongly believe that it is strong enough to take the company commercially to a very different position. Our focus is entirely on building that commercial position to show that our technology is being adopted all around the world. Revenues increase and the business increases with that. And I think with that increase, we will be in a very good position financially to take any actions that are then appropriate. And that is something that we will see when we move forward. The annual general meeting and the financial calendar are provided here. So the annual general meeting will be held on November 5th and the calendar is provided. There were a couple of significant events after the end of the period. I mentioned that we are now putting a lot of effort into the deals. So it is deals, deals, deals. And here you can get some reflection of these deals. So here we have four deals that were announced after the end of the fiscal year. They are all in the first piloting stage. We see some of them already moving also to the more production-oriented stage. So, for example, with Genom. The strategy and the commercial implementation are taking place all the time. And there are also results coming all the time. And the current fiscal year, I believe, will be the transformation in terms of the financial results as well. For Nightingale, we have set the target to double the revenue; reaching that will already make the company financially very different. And we strongly believe that we are in a very good position to reach that target. I think investors should follow our releases regarding the deals. The more we can win deals, the more there will be business, and the more there will be adoption for the technology. And I think that is the most important thing to follow right now. All right. That was the review of the agenda, except for one point left, which is the Q&A. So let's go to the Q&A, and as usual, John Randall will join me on stage.

John Randall
42:42 - 42:59

Good afternoon. Good afternoon viewers online; we have received a lot of questions. So I would say we jump right into it. Let's start with an easy one. So summarize the fiscal year in one word. How would you describe it?

Teemu Suna
43:01 - 43:45

Well, one word. Well, I think that word would be commercial, as I showed that after ten years of building the company as a technology firm, we are now becoming a commercial enterprise. It is a very difficult challenge. And that has been the focus. We have done tons of things internally to make this transformation happen. And I think we have been very successful in many of these things. And then I think the word for this fiscal year is deals.

John Randall
43:45 - 44:11

Okay. Yeah. Great. Thank you. You were also now answering already my last question. Okay. Or planned last question. Let's see how many questions we still receive. So please keep sending the questions. You are projecting 10 million in revenue for this fiscal year, with 2 million expected to come from the Archipelago Health case. So what assumptions underpin this forecast?

Teemu Suna
44:11 - 45:40

It is based on the pipelines across all the businesses. So the business has two different types of commercial deals that we are aiming for. There are the types of deals that are based on our ongoing sales activities. We try to increase the size of the funnel and it is the quantity of deals that is very important. So we build very traditional sales, build a big funnel, and we will land deals. That is one part of it. We are increasing the number of deals in the funnel across all of our businesses. Then we have another segment, which is basically a kind of strategic, landmark deal; that is a more strategic and targeted effort that we do. And this is also in parallel, but this forecast is based on the idea that these kinds of very operational sales activities will yield the result. Then if there are these strategic deals that we land, it accelerates the business growth even more. But it is not in the forecast. It is not based on that. It is what is happening operationally every day.

John Randall
45:41 - 45:52

So how much of the projected revenue is already secured in the order book, and how much still needs to be converted from the open pipeline or the sales pipeline?

Teemu Suna
45:52 - 47:00

Yeah. Well, obviously, I cannot reveal the exact numbers, but you can naturally make a bit of a reflection. If you look at the results. The result that we achieved in the past fiscal year, excluding the 2 million from that single project, remains consistent. This was this kind of a flagship project. We still managed to achieve 5.5 million, and this is based very much on our operational sales activities. I am not expecting this to decrease. All of the segments are growing. So maybe based on that, you can imagine that we are in a pretty good position to reach this target. Of course, it's not easy, but you should not make targets that are easy to reach. So I think we are in a very confident position that we will figure it out. And I think for a company, doubling the revenue is quite acceptable.

John Randall
47:02 - 47:18

Yes. There is a lot of interest in the split between research sales and healthcare sales. So if you can comment on and share some insights, what was the split past fiscal year and what can be expected this fiscal year?

Teemu Suna
47:18 - 48:47

I can talk a bit about how the trend looks. Looking backwards, only a very small part of the business has been healthcare business. It is very strongly research driven. Now if I take a look at these pipelines, how will this look in the future? I can see a moment when it reaches a 50/50 balance. I am not saying it happens over this fiscal year. But when I look at the forecast. Looking out the window, I can already see the model. The moment that this is likely to take place. So what this means is that the healthcare activities and the pipelines within the healthcare businesses are all growing. And with that growth, of course, the relative part of that business is getting bigger and bigger and bigger. So that is where we are. Of course, there can be individual projects that change the ratio temporarily. But if looking at the trend line, I think it's very clear that there is a lot of traction around healthcare businesses around the world.

John Randall
48:48 - 49:12

Yeah. Thank you. So let's talk a bit more about this partnership. You have announced some pilots, and you mentioned that some of the customers are already in the production phase. So how many of these partnerships are currently generating revenue, and how does the revenue growth look in terms of these partnerships that you have announced?

Teemu Suna
49:12 - 50:21

Yeah. So basically, almost all of the partnerships generate some revenue. But of course, when we are in the pilot stage, revenue is very small. And now I would also say that most of the deals by nature are deals that ramp up step by step. So you do not go to big volumes immediately; you go step by step. So the partner or the customer introduces our technology to their customers, and then they start building it step by step. So it takes some time to build up the revenues. And that is just the nature of this business. I think nobody is in a position to go and say, oh, you take this deal and then you commit to run like a million samples per year. I think nobody is in that position. There are, however, some strategic partnerships that would include these types of commitments, which would drive the volumes significantly higher. Much higher.

John Randall
50:23 - 50:27

Can we expect these kinds of partnerships to be announced in the near future?

Teemu Suna
50:27 - 50:28

Yes.

John Randall
50:28 - 50:46

Okay. So let's move to the U.S. And you already mentioned during a presentation some of the highlights from that market, but can you provide us with an update on activities and the progress in the US. So what can we expect from the US this fiscal year.

Teemu Suna
50:46 - 53:10

Yeah. Yeah. The US of course is where I look when I see what is happening in global healthcare. I talk a lot about these health platforms, which are often wearable companies or entities that offer other digital health solutions at the moment. What we see in the market is that these are products that are. They have the wearable, they have some AI, and they have some different elements. But the next generation of these products will be much more integrated solutions. The connection to the actual health outcomes will become more and more important. Because if you build something for humans, you need to remember it is not a product just for biohackers. It sounds nice in theory. In practice, it is not interesting. What is interesting is that if you can connect your lifestyle to your actual risks and avoid diseases. That is what we all want. We want to live healthy. And all of that development takes place in the United States. The United States also has a very strong opportunity landscape. Opportunity landscape in healthcare accounts that we are pursuing. We are going after. So it is a very good market for our technology and the journey to get there first was building the laboratory and getting the lab approval, which we received. Now we have been building the commercial team in the US. We have a person on the ground as part of the management team. Also, you have a responsibility to take ownership of the US business. We have put a lot of effort and resources into building it up, and in terms of product launches, you should be looking at the second half of our fiscal year. We are expecting to see some launches happening. So we are making strong progress in the US as well.

John Randall
53:12 - 53:43

That is great. Let's move to Singapore. Lots of things are going on there and a lot of questions are also related to Singapore. So the new report that you mentioned has been launched. What has been the feedback that you have received from your customers and clinics? And in the same way, can you answer the question of how many of these clinics are actively ordering today? And then a third question: has there been a significant change after you have launched the new product in Singapore?

Teemu Suna
53:43 - 55:03

Yeah. I think we need to look at this through the market feedback and the customer feedback. And now with the new product, the customer feedback has been significantly improved. So I think with the new product, we made quite significant changes to the product. I would say that the previous product looked a bit like a product built by engineers. Now the product we have is built for humans. It is easier to read, it is easier to understand, it is easier to use. It is simpler. And this applies. It is easier to use for the clinicians. It's easier to use for the patients. So, the product-market fit. I think for the first time, I feel that it is very good and very strong. The commercial numbers and the growth, as I mentioned, the Singapore market particularly is this kind of a step-by-step market. We are making good progress over there. You don't see it yet in the numbers, but we have a very strong plan to also show it in the numbers over this ongoing fiscal year.

John Randall
55:04 - 55:25

Thank you. There are a lot of questions also about the financial position of Nightingale Health. So I will save some time also for these questions. So what are the key factors that need to fall into place to achieve a successful turnaround to positive cash flow and profitability.

Teemu Suna
55:26 - 57:07

So, winning deals. That is the very short answer. I think this is a bit of a classical technology company position where we have built something that the earlier market had difficulties understanding, but now, very clearly, the market has transformed because of the pandemic and AI. Now everything is focused around this because AI enables the combination of different data modalities together. If you want to build a great health platform, you need great AI, you need great digital health data, including the wearable data, you need great molecular data, and you need great brand and marketing. And like all of that, you need all of these four to be at the top of the world. And now with the molecular data, it is not enough to measure this like standard biomarkers. You need to connect and provide a link to the actual outcomes. Because again, the user of the platform wants to avoid a disease. The user of the platform does not want to have better LDL. It is a very different concept to have. What was the question?

John Randall
57:07 - 57:13

I forget there were questions about how the turnaround will happen to reach profitability.

Teemu Suna
57:13 - 58:17

Yeah, yeah. By increasing adoption, we are leveraging these huge platforms. We have the same trends also ongoing in healthcare. So it is not only these consumer-facing platforms, it is also in healthcare winning the deals. And getting the adoption. It is very likely to increase the adoption all around the world. Everybody has the same problem. So there is no magic trick to reaching profitability like this. And in this way, the only way to reach it is to win deals around the world. And for that, I think we have the structure, we have the position, and we have made the investments we have. Very good. We are in a very good position to win the deals. And when we win the deals, the finances will turn around. Financial performance is a result of winning the deals. So that is what we are going to do.

John Randall
58:17 - 58:42

Yes. So we have two minutes left of this session. And there are still many questions that are left unanswered. But the last one is a question about the runway of the company and also how are you then going to do it all to create enough room for go-to-market investments and create headroom for commercialization? So can you comment something around this?

Teemu Suna
58:42 - 59:46

Yeah. So the runway is healthy and I strongly believe it is long enough to achieve the commercial breakthrough, and when we do that, the company will be in an excellent position to look over various financial options. It is important to remember that we are essentially debt-free. So we have multiple avenues after that. Now the focus is to do the commercial breakthrough for that. The runway is long enough in terms of marketing investments and all of that. I am not very worried about it because we are a B2B company. Our sales and marketing efforts are focused on a limited number of customers, which we can manage. The cost structure we have in place is, in the big picture, strong enough to achieve the breakthrough. And I think that puts us in a pretty good position also in terms of the runway and in terms of the current financial position.

John Randall
59:47 - 59:56

Thank you, Teemu. That was all from the Q&A session today. I will give the final word to you before we end this session. So please go ahead.

Teemu Suna
59:56 - 60:40

Thank you, Jana. So I think we are now in a very exciting financial year for Nightingale. We are putting all of our efforts and skills into achieving the commercial breakthrough. And when we do that, I think there will be very exciting applications for people to have a healthier life. So we will continue with that mission. And we will come back again in half a year to share with you what we have achieved. So thank you and have a nice day.

John Randall
60:40 - 60:41

Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…